INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 1 OF 2

ATTORNEY DOCKET	APPLICATION NO.
25352-0011	09/748,665
APPLICANT(S)	
Richard Sportsman et al.	
FILING DATE	ART UNIT
December 21, 2000	1617

U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)
GV	1	5,217,869	6/1993	Kauvar	435/7.9	
GV	2	5,300,425	4/1994	Kauvar	435/7.9	
GV	3	5,587,293	12/1996	Kauvar et al.	435/7.21	
GV	4	6,329,431	12/2001	Sportsman et al.	514/598	

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION
GV	5	EP	0 172 427	2/1986	Shin-Etsu Chemical Co., Ltd.	
GV	6	WO	95/23231	8/1995	Max Planck Institute	
GV	7	WO	96/30762	10/1996	Merck & Co. Inc.	
GV	8	WO	96/40276	12/1996	Sugen, Inc.	

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
GV	9	Brinkworth et al., "Non-peptidic anti-AIDS agents: inhibition of HIV-1 proteinase by disulfonates", *Biochem. Biophys. Res. Commun.*, **188**(2), 624-630 (1992)
	10	Desbois-Mouthon et al., "Severe resistance to insulin and insulin-like growth-factor-I in cells from a patient with leprechaunism as a result of two mutations in the tyrosine kinase domain of the insulin receptor", *Metabolism*, **45**, 1493-1500 (1996)
	11	Hubbard, "Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog", *EMBO J.*, **16**, 5572-5581 (1997)
	12	Hubbard et al., "Crystal structure of the tyrosine kinase domain of the human insulin receptor", *Nature*, **372**, 746-754 (1994)
	13	Kirchberger et al., "Studies of the interaction of NADH oxidase from *Thermus thermphilus* HB8 with triazine dyes", *J. Chromatogr. A*, **668**, 153-164 (1994)
	14	Kletzien et al., "Enhancement of adipocyte differentiation by an insulin-sensitizing agent", *Mol. Pharmacol.*, **41**, 393-398 (1992)
	15	Kobayashi et al., "Pioglitazone increases insulin sensitivity by activating insulin receptor kinase", *Diabetes*, **41**, 476-483 (1992)
	16	Kohanski, "Insulin receptor autophosphorylation. II. Determination of autophosphorylation sites by chemical sequence analysis and identification of the juxtamembrane sites", *Biochem.*, **32**, 5773-5780 (1993)
GV	17	Kole et al., "A synthetic peptide derived from the COOH-terminal domain of the insulin receptor specifically enhances insulin receptor signaling", *J. Biol. Chem.*, **271**, 31619-31626 (1996)

EXAMINER'S SIGNATURE	DATE CONSIDERED
S. V—	3/20/04

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 2 OF 2

ATTORNEY DOCKET	APPLICATION NO.
25352-0011	09/748,665
APPLICANT(S)	
Richard Sportsman et al.	
FILING DATE	ART UNIT
December 21, 2000	1617

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
GV	18	Macaulay et al., "Mutagenic structure-function analysis of the cytoplasmic cysteines of the insulin receptor", *Biochem. J.*, **306**, 811-820 (1995)
	19	Maddux et al., "Evidence that insulin plus ATP may induce a conformational change in the beta subunit of the insulin receptor without inducing receptor autophosphorylation", *J. Biol. Chem.*, **266**, 6731-6736 (1991)
	20	Moller et al., "A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance", *J. Biol. Chem.*, **265**, 14979-14985 (1990)
	21	Ojala et al., "The X-ray crystal structure of the sulfonated azo dye Congo Red, a non-peptidic inhibitor of HIV-1 protease which also binds to reverse transcriptase and amyloid proteins", *Antiviral. Chem. Chemother.*, **6**, 25-33 (1995)
	22	O'Neill et al., "Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system", *Mol. Cell Biol.*, **14**, 6433-6442 (1994)
	23	Rafaeloff et al., "Transmembrane signalling by insulin via an insulin receptor mutated at tyrosines 1158, 1162, and 1163", *Biochem. Biophys. Res. Commun.*, **179**, 912-918 (1991)
	24	Rolband et al., "Deletion of the insulin receptor beta-subunit acidic domain results in enhanced metabolic signaling", *Endocrinology*, **133**, 1437-1443 (1993)
	25	Sung et al., "Regulation of biological functions by an insulin receptor monoclonal antibody in insulin receptor beta-subunit mutants", *Biochemistry*, **31**, 168-174 (1992)
	26	Ullrich et al., "Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes", *Nature*, **313**, 756-761 (1985)
GV	27	Wei et al., "Expression, characterization and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain", *J. Biol. Chem.*, **270**, 8122-8130 (1995)

EXAMINER'S SIGNATURE	DATE CONSIDERED
S. V.	3/20/04

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).